RT Journal Article
SR Electronic
T1 Reduction of Inflammation Drives Lipid Changes in Ankylosing Spondylitis
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.150193
DO 10.3899/jrheum.150193
A1 Sjoerd C.  Heslinga
A1 Mike J.  Peters
A1 Marieke M.  ter Wee
A1 Irene E.  van der Horst-Bruinsma
A1 Alper M.  van Sijl
A1 Yvo M.  Smulders
A1 Michael T.  Nurmohamed
YR 2015
UL http://www.jrheum.org/content/early/2015/08/26/jrheum.150193.abstract
AB Objective To investigate the effects of changing inflammation on lipid levels in ankylosing spondylitis. Methods In a cohort of 230 patients, lipid levels were measured at baseline and after 52 weeks of treatment with tumor necrosis factor-α–blocking agents (anti-TNF). Results Total cholesterol (TC; +4.6%), low-density lipoprotein cholesterol (+4.3%), and high-density lipoprotein cholesterol (HDL-C; +3.7%) increased upon treatment. Changes were most evident in patients with substantial reduction in inflammatory levels (TC +8.2% vs +1.6% and HDL-C +8.3% vs +2.2% in patients with C-reactive protein ≥ 10 mg/l normalizing upon treatment vs CRP < 10 mg/l throughout treatment period). Conclusion Anti-TNF therapy results in lipid changes mostly when inflammation is appreciably modified.